Comparison between multiparametric MRT and FET-PET/MRT in regard of therapy evaluation and differentiation of vital tumor, therapy-associated transformation of glioma, depending on the WHO-classified (2016) mutation status

Comparison between multiparametric MRT and FET-PET/MRT in regard of therapy evaluation and differentiation of vital tumor, therapy-associated transformation of glioma, depending on the WHO-classified (2016) mutation status - NR_Gliom-04

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00014191

Enrollment

200

Registered

2018-03-02

Start date

2018-05-03

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C71

Interventions

Group 1: Acquisition of additional data via MR-sequences to measure ASL-perfusion and motion correction.

Eligibility

Sex/Gender

All

Age

19 Years to 99 Years

Inclusion criteria

Inclusion criteria: histopathol.-confirmed astrocytoma or oligodendrogliom (WHO grading II-IV), known molecular characterisation based on the WHO-classification 2016 for following subgroups: IDH-negative astrocytoma, IDH-positive astrocytoma and oligodendroglioma, scheduled radio- or chemotherapy, age =18 years, written informed consent.

Exclusion criteria

Exclusion criteria: Precnancy/breast feeding women, inability to lie quiescent for ca. 50 min (due to pain, claustrophobia, etc.), general contra-indication for MRT, contra-indication for MR-contrast agent Gadolinium, limited contractual capability.

Design outcomes

Primary

Measure	Time frame
Evaluation of MRT imaging parameter DSC-perfusion, ASL-perfusion, diffusion (curtosis), and FET-PET/MRT as marker for therapy response as well as differentiation between vital tumor and therapy-associated transformations in astrocytoma (w/o IDH mutation) and oligodendroglioma.	—

Secondary

Measure	Time frame
i) Explorative evaluation of the validity of parameter combinations in comparison to single imaging parameter, ii) explorative evaluation of the following parameter for therapy response evaluation and differentiation between therapy-induced transformations and vital tumor: ADC value, cholin enhancement, NAA-decrease, cholin/NAA-relation (spectroscopy), etc., iii) evaluation of the validity of study parameter for prognosis, iv) evaluation of motion artefacts during PET/MRT and their reduction by MR-based motion correction methods.	—

Measure

Time frame

i) Explorative evaluation of the validity of parameter combinations in comparison to single imaging parameter, ii) explorative evaluation of the following parameter for therapy response evaluation and differentiation between therapy-induced transformations and vital tumor: ADC value, cholin enhancement, NAA-decrease, cholin/NAA-relation (spectroscopy), etc., iii) evaluation of the validity of study parameter for prognosis, iv) evaluation of motion artefacts during PET/MRT and their reduction by MR-based motion correction methods.

—

Countries

Germany

Contacts

Public ContactCornelia Brendle

Radiologische Klinik, Universitätsklinikum Tübingen, Abt. Neuroradiologie

cornelia.brendle@med.uni-tuebingen.de07071-2986677

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026